Genmab — Juni 2023
-
Godmorgen
-
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE
NHL-1 Trial Evaluating Epcoritamab (DuoBody
CD3xCD2 -
Genmab præsenterer lovende data med epicoritamab - vil gå i dialog om godkendelse https://www.proinvestor.com/investornyt/1006884/genmab-praesenterer-lovende-data-med-epicoritamab-vil-ga-i-dialog-om-godkendelse
-
Genmab får sænket sit kursmål med 10 pct.https://www.proinvestor.com/investornyt/1006886/genmab-far-saenket-sit-kursmal-med-10-pct
-
Epco data i FL der blev offentliggjort her i nat var vel skuffende! Responsrate var god men varigheden ikke til tilstrækkelig!
-
Ja, Jeg har nok tolked meddelelsen forkert,
-
Blev lidt forvirret, da der stod “median duration of response not reached”
-
Yeah thanks. I was too fast with my conclusion. Sorry for the inconvenience caused.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind